Objective
In the current paradigm of gene expression, the structure of messenger RNA (mRNA) is a key element of posttranscriptional control because it modulates interactions with RNA-binding proteins (RBPs). RBPs typically recognize RNA-binding domains to form ribonucleoprotein complexes that ‘commit’ mRNAs to specific functions, and mutated or deregulated RBPs are implicated in multiple neurodegenerative diseases and cancer. Yet, the knowledge on the dynamic regulation of ribonucleoprotein complexes in mammalian cells is limited, mostly because the ‘structure’ and ‘specificity’ of RNA-protein interactions are amply unexplored. Recently, the host laboratory developed a new technique – hiCLIP – which identifies the transcriptome-wide RNA secondary structures (RNA duplexes) bound by particular RBPs, paving the way for pioneering research on the ‘structural determinants’ of RNA function in mammalian cells. In this context, N6-methyladenosine (m6A) is the most prevalent internal modification in mRNAs with critical functions in RNA stability, and seminal studies recently showed that m6A ‘marks’ destabilize in vivo RNA duplexes in the mammalian transcriptome. However, i) how m6A ‘marks’ regulate RNA-protein interactions that rely on RNA secondary structures is unknown, and ii) there is no systems-level elucidation of which RBPs are sensitive to m6A. Importantly, the ‘maintenance’ of m6A levels requires metabolic substrates and the m6A protein machinery is implicated in obesity and cancer. Collectively, these evidences point to a structural role of m6A in RNA function, and raise the compelling notion that metabolic control of m6A may represent a ‘regulatory module’ of gene expression in mammalian cells. The research proposed herein is designed to reveal the ‘regulatory principles’ of RNA structures in cell physiology, and the prospective results are likely to provide far-reaching insights on the significance of this process for metabolism-related diseases and cancer.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences medical biotechnology cells technologies stem cells
- medical and health sciences clinical medicine oncology
- medical and health sciences basic medicine immunology immunotherapy
- medical and health sciences basic medicine physiology homeostasis
- medical and health sciences health sciences nutrition obesity
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-EF-ST - Standard EF
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2015
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
WC1E 6BT LONDON
United Kingdom
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.